Current and Future Burden of Chronic Nonmalignant Liver Disease

Prowpanga Udompap, Donghee Kim, W. Ray Kim

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Disease burden is an important indicator of the state of health of a population. It can be measured as the frequency (eg, incidence and prevalence) of a condition or its effects including fatal and non-fatal health loss from disease (eg, disability-adjusted life years) as well as the financial costs (eg, direct healthcare costs and indirect healthcare expenditures related to lost income because of premature death). Accurate disease burden information is essential for policy-making such as prioritization of health interventions and allocation of resources. Chronic liver disease (CLD) causes substantial health and economic burden in the United States, where nearly 2 million deaths annually are attributable to CLD. In the recent past, overall mortality rate of CLD has been increasing. Viral hepatitis and alcoholic liver disease are thought to be the most common etiologies of chronic liver diseases. More recently, the prevalence of nonalcoholic fatty liver disease is rapidly increasing, and nonalcoholic steatohepatitis has become a leading indication for liver transplantation. In this article, we assemble available data on the burden of CLD in the United States, focusing on nonmalignant complications, whereas the impact on mortality and healthcare expenses of hepatocellular carcinoma, an important consequence of CLD, is discussed elsewhere.

Original languageEnglish (US)
Pages (from-to)2031-2041
Number of pages11
JournalClinical Gastroenterology and Hepatology
Volume13
Issue number12
DOIs
StatePublished - Nov 1 2015
Externally publishedYes

Fingerprint

Liver Diseases
Chronic Disease
Health
Delivery of Health Care
Alcoholic Liver Diseases
Premature Mortality
Quality-Adjusted Life Years
Resource Allocation
Mortality
Policy Making
Health Expenditures
Health Care Costs
Liver Transplantation
Hepatitis
Hepatocellular Carcinoma
Economics
Costs and Cost Analysis
Incidence
Population
Non-alcoholic Fatty Liver Disease

Keywords

  • Burden
  • Chronic Liver Disease
  • Health Economics

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Current and Future Burden of Chronic Nonmalignant Liver Disease. / Udompap, Prowpanga; Kim, Donghee; Kim, W. Ray.

In: Clinical Gastroenterology and Hepatology, Vol. 13, No. 12, 01.11.2015, p. 2031-2041.

Research output: Contribution to journalArticle

Udompap, Prowpanga ; Kim, Donghee ; Kim, W. Ray. / Current and Future Burden of Chronic Nonmalignant Liver Disease. In: Clinical Gastroenterology and Hepatology. 2015 ; Vol. 13, No. 12. pp. 2031-2041.
@article{41184469888147d4ad6010721a02c071,
title = "Current and Future Burden of Chronic Nonmalignant Liver Disease",
abstract = "Disease burden is an important indicator of the state of health of a population. It can be measured as the frequency (eg, incidence and prevalence) of a condition or its effects including fatal and non-fatal health loss from disease (eg, disability-adjusted life years) as well as the financial costs (eg, direct healthcare costs and indirect healthcare expenditures related to lost income because of premature death). Accurate disease burden information is essential for policy-making such as prioritization of health interventions and allocation of resources. Chronic liver disease (CLD) causes substantial health and economic burden in the United States, where nearly 2 million deaths annually are attributable to CLD. In the recent past, overall mortality rate of CLD has been increasing. Viral hepatitis and alcoholic liver disease are thought to be the most common etiologies of chronic liver diseases. More recently, the prevalence of nonalcoholic fatty liver disease is rapidly increasing, and nonalcoholic steatohepatitis has become a leading indication for liver transplantation. In this article, we assemble available data on the burden of CLD in the United States, focusing on nonmalignant complications, whereas the impact on mortality and healthcare expenses of hepatocellular carcinoma, an important consequence of CLD, is discussed elsewhere.",
keywords = "Burden, Chronic Liver Disease, Health Economics",
author = "Prowpanga Udompap and Donghee Kim and Kim, {W. Ray}",
year = "2015",
month = "11",
day = "1",
doi = "10.1016/j.cgh.2015.08.015",
language = "English (US)",
volume = "13",
pages = "2031--2041",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "12",

}

TY - JOUR

T1 - Current and Future Burden of Chronic Nonmalignant Liver Disease

AU - Udompap, Prowpanga

AU - Kim, Donghee

AU - Kim, W. Ray

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Disease burden is an important indicator of the state of health of a population. It can be measured as the frequency (eg, incidence and prevalence) of a condition or its effects including fatal and non-fatal health loss from disease (eg, disability-adjusted life years) as well as the financial costs (eg, direct healthcare costs and indirect healthcare expenditures related to lost income because of premature death). Accurate disease burden information is essential for policy-making such as prioritization of health interventions and allocation of resources. Chronic liver disease (CLD) causes substantial health and economic burden in the United States, where nearly 2 million deaths annually are attributable to CLD. In the recent past, overall mortality rate of CLD has been increasing. Viral hepatitis and alcoholic liver disease are thought to be the most common etiologies of chronic liver diseases. More recently, the prevalence of nonalcoholic fatty liver disease is rapidly increasing, and nonalcoholic steatohepatitis has become a leading indication for liver transplantation. In this article, we assemble available data on the burden of CLD in the United States, focusing on nonmalignant complications, whereas the impact on mortality and healthcare expenses of hepatocellular carcinoma, an important consequence of CLD, is discussed elsewhere.

AB - Disease burden is an important indicator of the state of health of a population. It can be measured as the frequency (eg, incidence and prevalence) of a condition or its effects including fatal and non-fatal health loss from disease (eg, disability-adjusted life years) as well as the financial costs (eg, direct healthcare costs and indirect healthcare expenditures related to lost income because of premature death). Accurate disease burden information is essential for policy-making such as prioritization of health interventions and allocation of resources. Chronic liver disease (CLD) causes substantial health and economic burden in the United States, where nearly 2 million deaths annually are attributable to CLD. In the recent past, overall mortality rate of CLD has been increasing. Viral hepatitis and alcoholic liver disease are thought to be the most common etiologies of chronic liver diseases. More recently, the prevalence of nonalcoholic fatty liver disease is rapidly increasing, and nonalcoholic steatohepatitis has become a leading indication for liver transplantation. In this article, we assemble available data on the burden of CLD in the United States, focusing on nonmalignant complications, whereas the impact on mortality and healthcare expenses of hepatocellular carcinoma, an important consequence of CLD, is discussed elsewhere.

KW - Burden

KW - Chronic Liver Disease

KW - Health Economics

UR - http://www.scopus.com/inward/record.url?scp=84944415081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944415081&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2015.08.015

DO - 10.1016/j.cgh.2015.08.015

M3 - Article

VL - 13

SP - 2031

EP - 2041

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 12

ER -